{"ticker": {"uuid": "d4226504-1adf-42b5-889c-434b2d7ed3fd", "symbol": "ANL", "name": "Adlai Nortye Ltd. American Depositary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025", "summary": "Adlai Nortye has announced that the first patient has been dosed in the intermittent weekly dosing (QW) arm of its Phase 1 clinical trial for AN9025, a pan-RAS(ON) inhibitor. This strategic move aims to evaluate whether weekly dosing can expand the therapeutic window, potentially", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328326/0/en/adlai-nortye-announces-first-patient-dosed-in-intermittent-weekly-dosing-arm-of-global-phase-1-trial-of-pan-ras-on-inhibitor-an9025.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T11:10:23", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Starts Weekly Dosing Test for RAS-Mutated Solid Tumors", "summary": "Adlai Nortye (NASDAQ: ANL) announced that the first patient has been dosed in the intermittent weekly (QW) arm of its global Phase 1 trial for AN9025, a pan-RAS(ON) inhibitor. This trial is for advanced or metastatic solid tumors with RAS mutations, with both once-daily (QD) and ", "url": "https://www.stocktitan.net/news/ANL/adlai-nortye-announces-first-patient-dosed-in-intermittent-weekly-pmaxbnzc3fz0.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:10:23", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye doses first patient in weekly trial arm of AN9025", "summary": "Adlai Nortye Ltd. has dosed the first patient in the weekly dosing arm of its Phase 1 clinical trial for AN9025, a pan-RAS(ON) inhibitor, in the United States. While the company's shares trade at $10.63 with a market capitalization of $425 million, InvestingPro suggests the stock", "url": "https://ca.investing.com/news/stock-market-news/adlai-nortye-doses-first-patient-in-weekly-trial-arm-of-an9025-93CH-4737091", "source_name": "Investing.com Canada", "published_at": "2026-07-16T11:10:23", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Adlai Nortye Ltd. \u2013 NASDAQ:ANL", "summary": "This article presents the enterprise value to EBITDA forward for Adlai Nortye Ltd. (NASDAQ: ANL). The content focuses on financial data for the company, accessible through TradingView, and provides no textual analysis or commentary beyond the headline and basic informational stru", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T00:44:47", "published_display": "15 Jul 2026 00:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists", "summary": "Adlai Nortye Ltd., a clinical-stage biotechnology company, has expanded its Scientific Advisory Board by appointing two prominent medical oncologists, Dr. David S. Hong and Dr. Piro Lito. This strategic move aims to leverage their expertise in clinical development, translational ", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326073/0/en/adlai-nortye-expands-scientific-advisory-board-with-appointment-of-two-leading-medical-oncologists.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T01:41:48", "published_display": "14 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye expands scientific advisory board with two oncologists", "summary": "Adlai Nortye Ltd. (NASDAQ:ANL) has appointed two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito, to its Scientific Advisory Board, enhancing its focus on RAS-targeted cancer therapies. The clinical-stage biotechnology company, despite a recent 9.6% stock decline", "url": "https://www.investing.com/news/company-news/adlai-nortye-expands-scientific-advisory-board-with-two-oncologists-93CH-4788084", "source_name": "Investing.com", "published_at": "2026-07-14T01:41:48", "published_display": "14 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Adlai Nortye Expands Scientific Advisory Board With Appointment of Two Leading Medical Oncologists", "summary": "Adlai Nortye has expanded its Scientific Advisory Board by appointing two eminent medical oncologists, Dr. Andrew Zelenetz and Dr. Jiaxin Niu. This strategic move aims to strengthen the company's clinical development and scientific innovation, particularly in oncology. The new ad", "url": "https://www.moomoo.com/news/post/72856396/press-release-adlai-nortye-expands-scientific-advisory-board-with-appointment?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T13:41:55", "published_display": "13 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Adlai Nortye expands scientific advisory board with two oncologists By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOQUFRTENRVzAtT3VOZFMzWk9RYW8xWGptSDVFMnB2aVlhZndrd2JUT3VzSVZVYUVMeWJ5a2tDemttNVRyTEFTWnVwM2RpNU9fWE02WTZ5Qkw4czdTYnRqZ0J4WEVfVU9ZZ3dJcVdIUk9zVXVHSFFOanV0eXZpeWptYjE1RmxmQUx6aFJhUWhlZ3dHdEQwV1NvTE5LNFJsNnlUYnhwRG56T1dRRU5fcTJQX0xpdzdURWp1UC0wNzB6OUh6cG1lcjFn?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-13T11:31:03+00:00", "published_display": "13 Jul 2026 11:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Expands Scientific Advisory Board with Appointments of Dr. David S. Hong and Dr. Piro Lito", "summary": "Adlai Nortye Ltd., a clinical-stage biotechnology company, announced the expansion of its Scientific Advisory Board with the appointments of Dr. David S. Hong and Dr. Piro Lito. These additions aim to enhance the company's oncology expertise, particularly in advancing its RAS inh", "url": "https://www.quiverquant.com/news/Adlai+Nortye+Expands+Scientific+Advisory+Board+with+Appointments+of+Dr.+David+S.+Hong+and+Dr.+Piro+Lito", "source_name": "Quiver Quantitative", "published_at": "2026-07-13T11:11:53", "published_display": "13 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two cancer drug specialists join Adlai Nortye\u2019s science board", "summary": "Adlai Nortye (NASDAQ: ANL), a clinical-stage biotechnology company, has expanded its Scientific Advisory Board by appointing leading medical oncologists Dr. David S. Hong and Dr. Piro Lito. These additions aim to strengthen the company's R&D strategy and clinical development, par", "url": "https://www.stocktitan.net/news/ANL/adlai-nortye-expands-scientific-advisory-board-with-appointment-of-isezkoz6l5od.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:10:59", "published_display": "13 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR \u2013 SWB:N2U0", "summary": "This page from TradingView provides financial data for Adlai Nortye Ltd. Sponsored ADR (SWB:N2U0), specifically focusing on its enterprise value to EBITDA forward metric. The content highlights various functionalities and tools offered by TradingView, such as charting libraries, ", "url": "https://www.tradingview.com/symbols/SWB-N2U0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T12:17:42", "published_display": "09 Jul 2026 12:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Adlai Nortye Ltd. \u2013 NASDAQ:ANL", "summary": "This article focuses on the enterprise value to EBIT forward metric for Adlai Nortye Ltd., traded on NASDAQ under the symbol ANL. It appears to be a financial data point presented by TradingView, indicating a specific financial ratio for the company. The content itself seems to b", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T15:11:05", "published_display": "29 Jun 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Adlai Nortye Ltd. Sponsored ADR \u2013 FWB:N2U0", "summary": "The article focuses on the \"Price to sales forward\" financial metric for Adlai Nortye Ltd. Sponsored ADR, traded on the Frankfurt Stock Exchange under the symbol N2U0. It indicates that the market was closed with no trades when the data was accessed. The content is primarily a da", "url": "https://www.tradingview.com/symbols/FWB-N2U0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:40:26", "published_display": "27 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Adlai Nortye Ltd. Sponsored ADR \u2013 FWB:N2U0", "summary": "This article provides financial data on the Enterprise Value to EBIT forward for Adlai Nortye Ltd. Sponsored ADR (FWB:N2U0) on the Frankfurt Stock Exchange. It indicates the market status as closed with no trades. The content primarily serves as a financial data point within a la", "url": "https://www.tradingview.com/symbols/FWB-N2U0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:37:14", "published_display": "27 Jun 2026 10:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Adlai Nortye Ltd. \u2013 NASDAQ:ANL", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNYUxRbFloazNHcUtCaVpGRk83RXEtMG9fMVEyemxCTl9BQk41WkxuNko0RW9EZFM1NHJzVjRPWlhOekdGX3BnbDRfXzcwZmRERXZlSlQ3MkE2eUR4eC11NXlfUU5JR0c2bk5LM1oyU2NSM0E5dzVyN0JUWmI4bTRFNDJjMlRxUm1KLXZGQ0ZEM0tfZER5Uk14a21aMA?oc=5", "source_name": "TradingView", "published_at": "2026-06-27T09:20:29+00:00", "published_display": "27 Jun 2026 09:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Adlai Nortye Ltd. \u2013 NASDAQ:ANL", "summary": "This article provides details on the number of shareholders for Adlai Nortye Ltd. (NASDAQ: ANL). It presents a financial data point showing the value and percentage change for the number of shareholders over a certain period, attributed to human analysis. The page is sourced from", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-26T23:41:04", "published_display": "26 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR \u2013 FWB:N2U0", "summary": "This article focuses on the enterprise value to EBITDA forward for Adlai Nortye Ltd. Sponsored ADR (FWB:N2U0), a company listed on the Frankfurt Stock Exchange. It provides financial data related to this metric, indicating its current value and any changes. The content appears to", "url": "https://www.tradingview.com/symbols/FWB-N2U0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:07", "published_display": "26 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ANL)", "summary": "This article provides an overview of Adlai Nortye Ltd. (NASDAQ: ANL) actuals and estimates, detailing available financial data and analyst estimates. It highlights resources for exploring reported financial data, comparing actual results with estimates, and visualizing trends ove", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:39:52", "published_display": "25 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This page provides forecast information for Adlai Nortye Ltd. (ANL) on the Nasdaq Stock Market. It indicates a current price target of 28.50 based on 6 analysts' 1-year forecasts, though specific max and min estimates are not provided. The content also includes sections for actua", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:11:11", "published_display": "25 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Adlai Nortye Ltd. \u2013 NASDAQ:ANL", "summary": "This article displays the future price-to-earnings ratio for Adlai Nortye Ltd. (NASDAQ: ANL). It presents a specific numerical value for this financial metric over a designated period, indicating its change and percentage change. The content appears to be a snapshot from a financ", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T16:41:19", "published_display": "24 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Adlai Nortye Ltd. Sponsored ADR \u2013 FWB:N2U0", "summary": "This article focuses on the enterprise value to revenue forward metric for Adlai Nortye Ltd. Sponsored ADR (FWB:N2U0). It highlights the company's financial data available on TradingView, serving as a financial snapshot for potential investors or analysts.", "url": "https://www.tradingview.com/symbols/FWB-N2U0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T13:41:19", "published_display": "24 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANL Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a financial overview of Adlai Nortye Ltd (ANL), detailing its revenue breakdown, profitability margins, and a comparison with its competitors. ANL reports a gross margin of 100.00% but negative operating and net margins, indicating challenges in converting o", "url": "https://intellectia.ai/en/stock/ANL/financials", "source_name": "Intellectia AI", "published_at": "2026-06-24T08:09:58", "published_display": "24 Jun 2026 08:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating", "summary": "Cantor Fitzgerald initiated coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with an overweight rating and a price target of $28 per share, suggesting approximately 180% upside. The biotechnology company focuses on the RAS pathway, developing AN9025, a Phase 1 panRAS inhibitor. Adlai ", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-initiates-adlai-nortye-stock-with-overweight-rating-93CH-4752236", "source_name": "Investing.com", "published_at": "2026-06-22T11:09:59", "published_display": "22 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd (ANL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for Adlai Nortye Ltd (ANL), highlighting analyst ratings, target prices, and a peer comparison. Based on five analysts, the stock has a \"Buy\" trend with a target price of USD 9.00, suggesting a potential upside. Key financial metrics like", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anl/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:34", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd (ANL) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Adlai Nortye Ltd (ANL), including its current stock price, market capitalization, and institutional shareholding data. It lists key institutional shareholders and their share movements, with UBS Financial Services, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anl/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:34", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd (ANL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses the revenue breakdown of Adlai Nortye Ltd (ANL) by business segments and regional contributions. However, it states that relevant data for these breakdowns have not yet been disclosed by the company. The page provides general stock information for ANL, inclu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anl/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:09:45", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd (ANL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Adlai Nortye Ltd (ANL)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports \"No Data\" for both historical dividend payments and stock splits, indicating a lack o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anl/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:09:45", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Adlai Nortye Ltd. Insider Trading Activity", "summary": "This article details an insider trading activity for Adlai Nortye Ltd. (ANL) reported on a Form 4 filing. The transaction involves Ji Ping, a director, receiving 136,667 American Depository Shares, which were distributed from a trust, rather than being purchased. The filing indic", "url": "https://www.stocktitan.net/sec-filings/ANL/form-4-adlai-nortye-ltd-insider-trading-activity-8d0f3958e963.html", "source_name": "Stock Titan", "published_at": "2026-06-10T16:10:13", "published_display": "10 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Adlai Nortye(ANL.US) With Buy Rating, Maintains Target Price $20", "summary": "H.C. Wainwright has reiterated its Buy rating for Adlai Nortye (ANL.US) and maintained a target price of $20. This indicates the firm's continued positive outlook on the company's stock.", "url": "https://www.moomoo.com/news/post/71272277/hc-wainwright-maintains-adlai-nortye-anlus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-10T01:38:56", "published_display": "10 Jun 2026 01:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANL Should I Buy", "summary": "This article analyzes whether Adlai Nortye Ltd (ANL) is a good investment, concluding it's a \"Buy\" for long-term investors based on strong analyst support and a promising pipeline, particularly its highly differentiated RAS-targeted programs. While there's no technical or options", "url": "https://intellectia.ai/en/stock/ANL/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-06-05T23:09:03", "published_display": "05 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye (ANL) Jefferies Global Healthcare Conference 2026 Summary", "summary": "The article summarizes Adlai Nortye's (ANL) presentation at the Jefferies Global Healthcare Conference 2026, highlighting key pipeline developments for its pan-RAS inhibitor AN9025, CEACAM5-targeting ADC AN4035, and next-generation IO program A025. It details scientific insights ", "url": "https://quartr.com/events/adlai-nortye-ltd-anl-jefferies-global-healthcare-2026-conference_FGfbMMUl", "source_name": "Quartr", "published_at": "2026-06-04T15:10:34", "published_display": "04 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye CEO Lu Yang sells $131 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNb1ZsRTBrN2lBSDJmaWVob1BfVUVUaGhFTTJqOWdNWi1kVWJGaEtwaDR1ak1VTl9DUF9ZVEdidEdFeHk2ZnVwZ0xyanJ4NlZpWk1QVFoyc3IzZ0RBRXhjbWhMTzBZOGdkb3p0dWNBLS1Ld21RaFZScE9EZ2QybkN3UndNZWFRTG5pTjVycFA1YmI2QU4temw3YVJ2SW9NNEFWYmxuWWpDNjJJcUx5UTVvR2MzUjlPOUk?oc=5", "source_name": "Investing.com", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adlai-nortye-ltd-sponsored-adr-160005544.html", "source_name": "Zacks", "published_at": "2026-05-20T16:00:05+00:00", "published_display": "20 May 2026 16:00", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPeHpxaUFaSTZLUHRfOVRIWFBTeGxaTjlkZWFLZlJHYzEyMDdtMzRIdG1pRWhMTVVPU21pN05RY09Uc3I4WGE3aFJ0aVIwRWFyQUpZRERiMFR2YnhKckpMOFVLNEJuZE5CdXBWSXJXbVlwbTg3a1Zha3hQbW1KMVo1TXN1cWFmc0gwTGQ3N3FvMEJyeHFTREk1c1B4SDM?oc=5", "source_name": "qz.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "H.C. Wainwright Sees \u201cPotential Best-in-Class Potency\u201d for Adlai Nortye\u2019s (ANL) Lead Asset, Lifts PT", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPV1JXN2gyZUZfRFNOR3VvWnZvQldrNjlmMUlZNGhwc3FhYmowRWc0VWdhVnZDWkVUUk8xTnpRcUMzd0F6ZlVHTWNjS2xyb2JtRjhlUmdRMGsyWG9TekR0N0lsQVJ2TUJPYWlTTVdDRDNDd2lkdkhVRFpPMHIxU09ZTkVzMjFzUkMxcVFqTDZhX3lFUW03M2xHbG1R?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye (ANL): 10 Tiny Stocks That Are On Fire Right Now", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adlai-nortye-anl-10-tiny-170051634.html", "source_name": "Insider Monkey", "published_at": "2026-04-29T17:00:51+00:00", "published_display": "29 Apr 2026 17:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye: Recapitalized, Refocused, But Still Too Early To Upgrade (NASDAQ:ANL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQS2tEV1o2ekJ6Tm5NVUo4TFowbldpQ1gwTV9rbDR1S0huRHIzVDN3NjZPa2JhLTgzZS12M2NSdGJYQ3BBemViUjZsSmMxeUllZTV0ZEhjTEhTOTlsSUktVEZZRmlvWGdOdEQ5WWJzMUV1cXY5a2NNWUtSYV9jS0psSUNZZUJqckFqMGFCZTBnSW93SnBVeF9KUnRHVmhXR2Q4dkZLZk5JRDNSeFpS?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Adlai Nortye raises $150M in oversubscribed private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOTEt2T0t5S2lhSmxUUk9zOU9tbzBzM0F5NlF4VFlTNDZId0JEQVBqWXEwdkgwTXZrVXpYVmI4UnVkWFJEa1pTQ0dlbmhQcVlEUC1ETVVXZ0JrUjdjb292VEdUd19DYkF2c3diZVVpdWRqVF8tdFBLNGN6MF9EZUx6M08yTnVBSUROYktWampUUGVYNlNBQk0ya1puT2VoV3RoeThlNU93clVZYU8xWENfVEVJbG04NXZP?oc=5", "source_name": "Investing.com", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Announces $150.0 Million Private Placement Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPZ2ZiNGl4RFBQMWppdmQ0R0pwQ2JFLTdMM3ZyYXV0cnBldTVoMkEwMTRaSGhiNlk0WkFMdVpzcTFhT2hIc2NQVUQ5ZjJWOGlTcUhnT0NDUU9lT2ZZVE1JVkdCeUJUSklqeGJyS21Ub3k4a0dZYlJnVEJDaURNR0dlbDBzMThDbDVhcEplZFhaZUMzWFR2bEFXb1JvaWx4NFdyd0FQeDNkZEx0em53UlgtSWxyMGRkakZSUW5uSktXQl9wRTBTRldWSVZ5S2VfQm1Xa2hnX05xOEp2NGs?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye (ANL) Loss Narrows To US$18.3 Million Challenging Bearish Cash Burn Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNLW9zWEpfNmRKb0R1X1RzTkJFYnBWNVdSVG5ENGZhcmNyZlJNbUhQNEZZV0V6MVhRSWtLeHJEVVZqZThBeEZjN3RDV1dlOFJIT3lsOXBVTnRVeThtRFJHUl9qTHNQR0RsTEJ4Y1dxYWREQVdRUGhscmd4eHdSMG9naEpNNXZOXzdsZ1RnYXpxS2Ixd0FUQTAyekF1bw?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd.'s (NASDAQ:ANL) market cap surged US$65m last week, retail investors who have a lot riding on the company were rewarded", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Individual investors are Adlai Nortye Ltd.'s (NASDAQ:ANL) biggest owners and were rewarded after market cap rose by US$65m last week", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQZ0NLTWp2M283ZmdONkpuaUpmRDAtZGVHV3JjN0MzcENoNnFiVHJMMV8zNTVNTVNYb3VDdkVYQzlxVHpDUEpQaFdBRi1lYjBPdW1JXzVhX1lqQ21NNlJKWTZHaUdsbFlXUjJiV2o0U1RjRzhXSG1maTdQUVc3Q3VFM2paQzJmdjd5OXRr?oc=5", "source_name": "Market source", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aggressive licensor, cancer-focused Adlai Nortye files for US IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQS18xVl9yTzYxMlFMczQyR2UwQTlOWVpjcmJPMWhZVTd4bUlfU0k4aXlFVE14NTViNmlUNFl3VktIYlZkWHE4U3BsZW5KUmZxNFA5Z0pBWWRTUS1xaUVnYi0tblNXN1N3aEdhMHZMYU10dGZVaExFSlpVUGotUHZqNUx2czNObW1qR2JTU2ZjVlItZ24weHhkcy1XYTh5cGcyeFoxT2ljaWg?oc=5", "source_name": "BioWorld News", "published_at": "2023-08-01T07:00:00+00:00", "published_display": "01 Aug 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025", "summary": "Adlai Nortye has announced that the first patient has been dosed in the intermittent weekly dosing (QW) arm of its Phase 1 clinical trial for AN9025, a pan-RAS(ON) inhibitor. This strategic move aims to evaluate whether weekly dosing can expand the therapeutic window, potentially", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328326/0/en/adlai-nortye-announces-first-patient-dosed-in-intermittent-weekly-dosing-arm-of-global-phase-1-trial-of-pan-ras-on-inhibitor-an9025.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T11:10:23", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Starts Weekly Dosing Test for RAS-Mutated Solid Tumors", "summary": "Adlai Nortye (NASDAQ: ANL) announced that the first patient has been dosed in the intermittent weekly (QW) arm of its global Phase 1 trial for AN9025, a pan-RAS(ON) inhibitor. This trial is for advanced or metastatic solid tumors with RAS mutations, with both once-daily (QD) and ", "url": "https://www.stocktitan.net/news/ANL/adlai-nortye-announces-first-patient-dosed-in-intermittent-weekly-pmaxbnzc3fz0.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:10:23", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye doses first patient in weekly trial arm of AN9025", "summary": "Adlai Nortye Ltd. has dosed the first patient in the weekly dosing arm of its Phase 1 clinical trial for AN9025, a pan-RAS(ON) inhibitor, in the United States. While the company's shares trade at $10.63 with a market capitalization of $425 million, InvestingPro suggests the stock", "url": "https://ca.investing.com/news/stock-market-news/adlai-nortye-doses-first-patient-in-weekly-trial-arm-of-an9025-93CH-4737091", "source_name": "Investing.com Canada", "published_at": "2026-07-16T11:10:23", "published_display": "16 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Adlai Nortye Ltd. \u2013 NASDAQ:ANL", "summary": "This article presents the enterprise value to EBITDA forward for Adlai Nortye Ltd. (NASDAQ: ANL). The content focuses on financial data for the company, accessible through TradingView, and provides no textual analysis or commentary beyond the headline and basic informational stru", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-15T00:44:47", "published_display": "15 Jul 2026 00:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists", "summary": "Adlai Nortye Ltd., a clinical-stage biotechnology company, has expanded its Scientific Advisory Board by appointing two prominent medical oncologists, Dr. David S. Hong and Dr. Piro Lito. This strategic move aims to leverage their expertise in clinical development, translational ", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326073/0/en/adlai-nortye-expands-scientific-advisory-board-with-appointment-of-two-leading-medical-oncologists.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T01:41:48", "published_display": "14 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye expands scientific advisory board with two oncologists", "summary": "Adlai Nortye Ltd. (NASDAQ:ANL) has appointed two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito, to its Scientific Advisory Board, enhancing its focus on RAS-targeted cancer therapies. The clinical-stage biotechnology company, despite a recent 9.6% stock decline", "url": "https://www.investing.com/news/company-news/adlai-nortye-expands-scientific-advisory-board-with-two-oncologists-93CH-4788084", "source_name": "Investing.com", "published_at": "2026-07-14T01:41:48", "published_display": "14 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Adlai Nortye Expands Scientific Advisory Board With Appointment of Two Leading Medical Oncologists", "summary": "Adlai Nortye has expanded its Scientific Advisory Board by appointing two eminent medical oncologists, Dr. Andrew Zelenetz and Dr. Jiaxin Niu. This strategic move aims to strengthen the company's clinical development and scientific innovation, particularly in oncology. The new ad", "url": "https://www.moomoo.com/news/post/72856396/press-release-adlai-nortye-expands-scientific-advisory-board-with-appointment?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T13:41:55", "published_display": "13 Jul 2026 13:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye expands scientific advisory board with two oncologists By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOQUFRTENRVzAtT3VOZFMzWk9RYW8xWGptSDVFMnB2aVlhZndrd2JUT3VzSVZVYUVMeWJ5a2tDemttNVRyTEFTWnVwM2RpNU9fWE02WTZ5Qkw4czdTYnRqZ0J4WEVfVU9ZZ3dJcVdIUk9zVXVHSFFOanV0eXZpeWptYjE1RmxmQUx6aFJhUWhlZ3dHdEQwV1NvTE5LNFJsNnlUYnhwRG56T1dRRU5fcTJQX0xpdzdURWp1UC0wNzB6OUh6cG1lcjFn?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-13T11:31:03+00:00", "published_display": "13 Jul 2026 11:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Expands Scientific Advisory Board with Appointments of Dr. David S. Hong and Dr. Piro Lito", "summary": "Adlai Nortye Ltd., a clinical-stage biotechnology company, announced the expansion of its Scientific Advisory Board with the appointments of Dr. David S. Hong and Dr. Piro Lito. These additions aim to enhance the company's oncology expertise, particularly in advancing its RAS inh", "url": "https://www.quiverquant.com/news/Adlai+Nortye+Expands+Scientific+Advisory+Board+with+Appointments+of+Dr.+David+S.+Hong+and+Dr.+Piro+Lito", "source_name": "Quiver Quantitative", "published_at": "2026-07-13T11:11:53", "published_display": "13 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two cancer drug specialists join Adlai Nortye\u2019s science board", "summary": "Adlai Nortye (NASDAQ: ANL), a clinical-stage biotechnology company, has expanded its Scientific Advisory Board by appointing leading medical oncologists Dr. David S. Hong and Dr. Piro Lito. These additions aim to strengthen the company's R&D strategy and clinical development, par", "url": "https://www.stocktitan.net/news/ANL/adlai-nortye-expands-scientific-advisory-board-with-appointment-of-isezkoz6l5od.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:10:59", "published_display": "13 Jul 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR \u2013 SWB:N2U0", "summary": "This page from TradingView provides financial data for Adlai Nortye Ltd. Sponsored ADR (SWB:N2U0), specifically focusing on its enterprise value to EBITDA forward metric. The content highlights various functionalities and tools offered by TradingView, such as charting libraries, ", "url": "https://www.tradingview.com/symbols/SWB-N2U0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T12:17:42", "published_display": "09 Jul 2026 12:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Adlai Nortye Ltd. \u2013 NASDAQ:ANL", "summary": "This article focuses on the enterprise value to EBIT forward metric for Adlai Nortye Ltd., traded on NASDAQ under the symbol ANL. It appears to be a financial data point presented by TradingView, indicating a specific financial ratio for the company. The content itself seems to b", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T15:11:05", "published_display": "29 Jun 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Adlai Nortye Ltd. Sponsored ADR \u2013 FWB:N2U0", "summary": "The article focuses on the \"Price to sales forward\" financial metric for Adlai Nortye Ltd. Sponsored ADR, traded on the Frankfurt Stock Exchange under the symbol N2U0. It indicates that the market was closed with no trades when the data was accessed. The content is primarily a da", "url": "https://www.tradingview.com/symbols/FWB-N2U0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:40:26", "published_display": "27 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Adlai Nortye Ltd. Sponsored ADR \u2013 FWB:N2U0", "summary": "This article provides financial data on the Enterprise Value to EBIT forward for Adlai Nortye Ltd. Sponsored ADR (FWB:N2U0) on the Frankfurt Stock Exchange. It indicates the market status as closed with no trades. The content primarily serves as a financial data point within a la", "url": "https://www.tradingview.com/symbols/FWB-N2U0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:37:14", "published_display": "27 Jun 2026 10:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Adlai Nortye Ltd. \u2013 NASDAQ:ANL", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNYUxRbFloazNHcUtCaVpGRk83RXEtMG9fMVEyemxCTl9BQk41WkxuNko0RW9EZFM1NHJzVjRPWlhOekdGX3BnbDRfXzcwZmRERXZlSlQ3MkE2eUR4eC11NXlfUU5JR0c2bk5LM1oyU2NSM0E5dzVyN0JUWmI4bTRFNDJjMlRxUm1KLXZGQ0ZEM0tfZER5Uk14a21aMA?oc=5", "source_name": "TradingView", "published_at": "2026-06-27T09:20:29+00:00", "published_display": "27 Jun 2026 09:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Adlai Nortye Ltd. \u2013 NASDAQ:ANL", "summary": "This article provides details on the number of shareholders for Adlai Nortye Ltd. (NASDAQ: ANL). It presents a financial data point showing the value and percentage change for the number of shareholders over a certain period, attributed to human analysis. The page is sourced from", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-26T23:41:04", "published_display": "26 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR \u2013 FWB:N2U0", "summary": "This article focuses on the enterprise value to EBITDA forward for Adlai Nortye Ltd. Sponsored ADR (FWB:N2U0), a company listed on the Frankfurt Stock Exchange. It provides financial data related to this metric, indicating its current value and any changes. The content appears to", "url": "https://www.tradingview.com/symbols/FWB-N2U0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:07", "published_display": "26 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ANL)", "summary": "This article provides an overview of Adlai Nortye Ltd. (NASDAQ: ANL) actuals and estimates, detailing available financial data and analyst estimates. It highlights resources for exploring reported financial data, comparing actual results with estimates, and visualizing trends ove", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:39:52", "published_display": "25 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANL Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This page provides forecast information for Adlai Nortye Ltd. (ANL) on the Nasdaq Stock Market. It indicates a current price target of 28.50 based on 6 analysts' 1-year forecasts, though specific max and min estimates are not provided. The content also includes sections for actua", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T14:11:11", "published_display": "25 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Adlai Nortye Ltd. \u2013 NASDAQ:ANL", "summary": "This article displays the future price-to-earnings ratio for Adlai Nortye Ltd. (NASDAQ: ANL). It presents a specific numerical value for this financial metric over a designated period, indicating its change and percentage change. The content appears to be a snapshot from a financ", "url": "https://www.tradingview.com/symbols/NASDAQ-ANL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T16:41:19", "published_display": "24 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Adlai Nortye Ltd. Sponsored ADR \u2013 FWB:N2U0", "summary": "This article focuses on the enterprise value to revenue forward metric for Adlai Nortye Ltd. Sponsored ADR (FWB:N2U0). It highlights the company's financial data available on TradingView, serving as a financial snapshot for potential investors or analysts.", "url": "https://www.tradingview.com/symbols/FWB-N2U0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T13:41:19", "published_display": "24 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANL Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a financial overview of Adlai Nortye Ltd (ANL), detailing its revenue breakdown, profitability margins, and a comparison with its competitors. ANL reports a gross margin of 100.00% but negative operating and net margins, indicating challenges in converting o", "url": "https://intellectia.ai/en/stock/ANL/financials", "source_name": "Intellectia AI", "published_at": "2026-06-24T08:09:58", "published_display": "24 Jun 2026 08:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating", "summary": "Cantor Fitzgerald initiated coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with an overweight rating and a price target of $28 per share, suggesting approximately 180% upside. The biotechnology company focuses on the RAS pathway, developing AN9025, a Phase 1 panRAS inhibitor. Adlai ", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-initiates-adlai-nortye-stock-with-overweight-rating-93CH-4752236", "source_name": "Investing.com", "published_at": "2026-06-22T11:09:59", "published_display": "22 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd (ANL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for Adlai Nortye Ltd (ANL), highlighting analyst ratings, target prices, and a peer comparison. Based on five analysts, the stock has a \"Buy\" trend with a target price of USD 9.00, suggesting a potential upside. Key financial metrics like", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anl/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:34", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd (ANL) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Adlai Nortye Ltd (ANL), including its current stock price, market capitalization, and institutional shareholding data. It lists key institutional shareholders and their share movements, with UBS Financial Services, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anl/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:34", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd (ANL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses the revenue breakdown of Adlai Nortye Ltd (ANL) by business segments and regional contributions. However, it states that relevant data for these breakdowns have not yet been disclosed by the company. The page provides general stock information for ANL, inclu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anl/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:09:45", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd (ANL) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Adlai Nortye Ltd (ANL)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports \"No Data\" for both historical dividend payments and stock splits, indicating a lack o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-anl/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:09:45", "published_display": "17 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Adlai Nortye Ltd. Insider Trading Activity", "summary": "This article details an insider trading activity for Adlai Nortye Ltd. (ANL) reported on a Form 4 filing. The transaction involves Ji Ping, a director, receiving 136,667 American Depository Shares, which were distributed from a trust, rather than being purchased. The filing indic", "url": "https://www.stocktitan.net/sec-filings/ANL/form-4-adlai-nortye-ltd-insider-trading-activity-8d0f3958e963.html", "source_name": "Stock Titan", "published_at": "2026-06-10T16:10:13", "published_display": "10 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Adlai Nortye(ANL.US) With Buy Rating, Maintains Target Price $20", "summary": "H.C. Wainwright has reiterated its Buy rating for Adlai Nortye (ANL.US) and maintained a target price of $20. This indicates the firm's continued positive outlook on the company's stock.", "url": "https://www.moomoo.com/news/post/71272277/hc-wainwright-maintains-adlai-nortye-anlus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-10T01:38:56", "published_display": "10 Jun 2026 01:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANL Should I Buy", "summary": "This article analyzes whether Adlai Nortye Ltd (ANL) is a good investment, concluding it's a \"Buy\" for long-term investors based on strong analyst support and a promising pipeline, particularly its highly differentiated RAS-targeted programs. While there's no technical or options", "url": "https://intellectia.ai/en/stock/ANL/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-06-05T23:09:03", "published_display": "05 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye (ANL) Jefferies Global Healthcare Conference 2026 Summary", "summary": "The article summarizes Adlai Nortye's (ANL) presentation at the Jefferies Global Healthcare Conference 2026, highlighting key pipeline developments for its pan-RAS inhibitor AN9025, CEACAM5-targeting ADC AN4035, and next-generation IO program A025. It details scientific insights ", "url": "https://quartr.com/events/adlai-nortye-ltd-anl-jefferies-global-healthcare-2026-conference_FGfbMMUl", "source_name": "Quartr", "published_at": "2026-06-04T15:10:34", "published_display": "04 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye CEO Lu Yang sells $131 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNb1ZsRTBrN2lBSDJmaWVob1BfVUVUaGhFTTJqOWdNWi1kVWJGaEtwaDR1ak1VTl9DUF9ZVEdidEdFeHk2ZnVwZ0xyanJ4NlZpWk1QVFoyc3IzZ0RBRXhjbWhMTzBZOGdkb3p0dWNBLS1Ld21RaFZScE9EZ2QybkN3UndNZWFRTG5pTjVycFA1YmI2QU4temw3YVJ2SW9NNEFWYmxuWWpDNjJJcUx5UTVvR2MzUjlPOUk?oc=5", "source_name": "Investing.com", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adlai-nortye-ltd-sponsored-adr-160005544.html", "source_name": "Zacks", "published_at": "2026-05-20T16:00:05+00:00", "published_display": "20 May 2026 16:00", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPeHpxaUFaSTZLUHRfOVRIWFBTeGxaTjlkZWFLZlJHYzEyMDdtMzRIdG1pRWhMTVVPU21pN05RY09Uc3I4WGE3aFJ0aVIwRWFyQUpZRERiMFR2YnhKckpMOFVLNEJuZE5CdXBWSXJXbVlwbTg3a1Zha3hQbW1KMVo1TXN1cWFmc0gwTGQ3N3FvMEJyeHFTREk1c1B4SDM?oc=5", "source_name": "qz.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Sees \u201cPotential Best-in-Class Potency\u201d for Adlai Nortye\u2019s (ANL) Lead Asset, Lifts PT", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPV1JXN2gyZUZfRFNOR3VvWnZvQldrNjlmMUlZNGhwc3FhYmowRWc0VWdhVnZDWkVUUk8xTnpRcUMzd0F6ZlVHTWNjS2xyb2JtRjhlUmdRMGsyWG9TekR0N0lsQVJ2TUJPYWlTTVdDRDNDd2lkdkhVRFpPMHIxU09ZTkVzMjFzUkMxcVFqTDZhX3lFUW03M2xHbG1R?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye (ANL): 10 Tiny Stocks That Are On Fire Right Now", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/adlai-nortye-anl-10-tiny-170051634.html", "source_name": "Insider Monkey", "published_at": "2026-04-29T17:00:51+00:00", "published_display": "29 Apr 2026 17:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye: Recapitalized, Refocused, But Still Too Early To Upgrade (NASDAQ:ANL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQS2tEV1o2ekJ6Tm5NVUo4TFowbldpQ1gwTV9rbDR1S0huRHIzVDN3NjZPa2JhLTgzZS12M2NSdGJYQ3BBemViUjZsSmMxeUllZTV0ZEhjTEhTOTlsSUktVEZZRmlvWGdOdEQ5WWJzMUV1cXY5a2NNWUtSYV9jS0psSUNZZUJqckFqMGFCZTBnSW93SnBVeF9KUnRHVmhXR2Q4dkZLZk5JRDNSeFpS?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye raises $150M in oversubscribed private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOTEt2T0t5S2lhSmxUUk9zOU9tbzBzM0F5NlF4VFlTNDZId0JEQVBqWXEwdkgwTXZrVXpYVmI4UnVkWFJEa1pTQ0dlbmhQcVlEUC1ETVVXZ0JrUjdjb292VEdUd19DYkF2c3diZVVpdWRqVF8tdFBLNGN6MF9EZUx6M08yTnVBSUROYktWampUUGVYNlNBQk0ya1puT2VoV3RoeThlNU93clVZYU8xWENfVEVJbG04NXZP?oc=5", "source_name": "Investing.com", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Announces $150.0 Million Private Placement Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPZ2ZiNGl4RFBQMWppdmQ0R0pwQ2JFLTdMM3ZyYXV0cnBldTVoMkEwMTRaSGhiNlk0WkFMdVpzcTFhT2hIc2NQVUQ5ZjJWOGlTcUhnT0NDUU9lT2ZZVE1JVkdCeUJUSklqeGJyS21Ub3k4a0dZYlJnVEJDaURNR0dlbDBzMThDbDVhcEplZFhaZUMzWFR2bEFXb1JvaWx4NFdyd0FQeDNkZEx0em53UlgtSWxyMGRkakZSUW5uSktXQl9wRTBTRldWSVZ5S2VfQm1Xa2hnX05xOEp2NGs?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye (ANL) Loss Narrows To US$18.3 Million Challenging Bearish Cash Burn Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNLW9zWEpfNmRKb0R1X1RzTkJFYnBWNVdSVG5ENGZhcmNyZlJNbUhQNEZZV0V6MVhRSWtLeHJEVVZqZThBeEZjN3RDV1dlOFJIT3lsOXBVTnRVeThtRFJHUl9qTHNQR0RsTEJ4Y1dxYWREQVdRUGhscmd4eHdSMG9naEpNNXZOXzdsZ1RnYXpxS2Ixd0FUQTAyekF1bw?oc=5", "source_name": "Market source", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adlai Nortye Ltd.'s (NASDAQ:ANL) market cap surged US$65m last week, retail investors who have a lot riding on the company were rewarded", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Individual investors are Adlai Nortye Ltd.'s (NASDAQ:ANL) biggest owners and were rewarded after market cap rose by US$65m last week", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQZ0NLTWp2M283ZmdONkpuaUpmRDAtZGVHV3JjN0MzcENoNnFiVHJMMV8zNTVNTVNYb3VDdkVYQzlxVHpDUEpQaFdBRi1lYjBPdW1JXzVhX1lqQ21NNlJKWTZHaUdsbFlXUjJiV2o0U1RjRzhXSG1maTdQUVc3Q3VFM2paQzJmdjd5OXRr?oc=5", "source_name": "Market source", "published_at": "2026-01-28T08:00:00+00:00", "published_display": "28 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aggressive licensor, cancer-focused Adlai Nortye files for US IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQS18xVl9yTzYxMlFMczQyR2UwQTlOWVpjcmJPMWhZVTd4bUlfU0k4aXlFVE14NTViNmlUNFl3VktIYlZkWHE4U3BsZW5KUmZxNFA5Z0pBWWRTUS1xaUVnYi0tblNXN1N3aEdhMHZMYU10dGZVaExFSlpVUGotUHZqNUx2czNObW1qR2JTU2ZjVlItZ24weHhkcy1XYTh5cGcyeFoxT2ljaWg?oc=5", "source_name": "BioWorld News", "published_at": "2023-08-01T07:00:00+00:00", "published_display": "01 Aug 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 52, "sentiment_summary": {"positive": 19, "negative": 3, "neutral": 30, "score": 58, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 15.4, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 4.0, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 9.87, "latest_week": "2026-07-10", "one_week_move": 4.0, "four_week_move": -4.4, "twelve_week_move": -38.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.735695, "market_dynamics_buy_signal": false, "relative_strength": 52.893351, "fair_value_gap": 82.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 40.8824, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.0% over one week, -4.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 13}, {"label": "Market source", "count": 8}, {"label": "Investing.com", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "Investing.com Canada", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 6}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+4.0% over one week, -4.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025"}], "updated_at": "2026-07-16T14:30:37.419185+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}